About us 

Management team

Samuel Svensson, CEO
Samuel Svensson PhD (Pharmacology) has been working for more than 10 years at Neuroscience AstraZeneca R&D Södertälje, Sweden responsible for the development of the amyloid selective PET radiotracer 18F-AZD4694 recently acquired by Navidae Biopharmaceuticals. He is a cofounder and Senior Principal Scientist at the Alzecure Research foundation and chairman at BioPercept AB. Samuel Svensson is an adjunct Professor in Pharmacology at Div for Drug Research, Linkoping University.

Scientific Advisory Board

Professor David J Burn
Director, Institute for Ageing and Health, and Professor of Movement Disorders Neurology
Clinical Ageing Research Unit
Newcastle University

Professor Anthony E. Lang
Movement Disorders Centre
Toronto Western Hospital

Professor Irene Litvan
Tasch Endowed Professor in Parkinson's Disease Research
Director of the Movement Disorder Center
University of California, San Diego

Professor Thomas Perlmann
Karolinska Institutet Stockholm

Professor Michael A. Schwarzschild
Harvard Medical School, Boston

Professor Per Svenningsson
Karolinska Institutet Stockholm

Professor Håkan Widner
Lund University

Professor Stefan Lorenzl
Ludwig Maximilian University of Munich

Board of Directors

Sten Mortstedt (Chairman)
Sten Mortstedt, a businessman and philanthropist, has a consistent track record during a period of over 40 years, of building profitable and sustainable businesses. He currently serves as Executive Chairman of CLS Holdings plc, a pan-European property company which he established in 1987 and took to a listing on the main market of the London Stock Exchange in 1994. In addition to his focus on property, he has been commercially active in a number of investment areas outside the property arena and has seen a number of the companies in which he has invested through to successful stock exchange listings or trade sales.

Håkan Björklund (member)
Håkan Björklund, Ph.D (neuroscience) is a consultant to Avista Capital Partners and serves as Chairman of H. Lundbeck A/S. He has years of international experience from the pharmaceutical industry. Having been in charge of the research activities of Astra AB for a number of years, he was later responsible for the company's sales and marketing in the Nordic region, certain countries in Europe and South Africa. From 1999-2011 he was CEO of Nycomed GmbH which was sold to Takeda Pharmaceuticals in September 2011 for 9.6 billion Euros. Håkan Björklund also serves on the boards of Atos Medical AB and Coloplast A/S.

Björn Bloth (Vice Chairman)
Björn Bloth, MD, PhD, Associated Professor, works as scientific and medical advisor to several foundations and organisations. He has a PhD in Medical microbiology and immunology and has also a board certification in Internal medicine. He has been practicing medicine for many years.

Ingvar Dahlqvist (member)
Ingvar Dahlqvist has a BA in economy. He has for several years worked in Europe for a French industrial group as a Business Controller and Financial Director, for market development and as a Managing Director and is today a member and a chairman of the board of a number of Swedish and French companies. He is also the chairman of the Parkinson association in the south of Sweden and also a member of the election committee of the national Parkinson association in Sweden.

Peter Zonabend (member)
Peter Zonabend has a B.Sc. in BA and Econ, LL.M and EMLE. He has worked as a lawyer in Stockholm prior to joining the Mortstedt family's investment company where he acts as the Managing Director as well as general counsel to the Mortstedt sphere. Peter Zonabend serves on several boards of both listed and unlisted companies.

Angela Crawley (member)
Angela Crawley has a BA in Psychology and a MA in Psychotherapy. She has a private practice in the London area.